Find a Physician

Dr David Lord
Radiology Department
Vascular Birthmarks Program
Childrens Hospital Westmead
Locked Bag 4001
Westmead NSW 2145
Sydney Australia
www.chw.edu.au/site/directory/entries/vascular_birthmarks.htm

Dr. Tony Moore
Adelaido Plastic Surg. Assoc.
Memorial Hospital North Adelaide,
S. Australia 8267-1800

Dr Philip Bekhor
Director, Laser Unit
Royal Children's Hospital
Melbourne, Australia
and
Laser Dermatology
503 Elgar Rd
Box Hill, Melbourne
Victoria
Phone 61 3 9890 1844
www.laserdermatology.com.au

Has your baby developed infantile hemangioma, also known as strawberry birthmark?

Three centres in Australia are conducting a research study looking infants with proliferating infantile hemangiomas (IHO) that require medication. This study will evaluate the use of an investigational drug, V00400 SB (also known propranolol) in the treatment of hemangiomas.

THIS STUDY MAY BE APPROPRIATE FOR YOUR CHILD IF HE/SHE:
· Is between 35-150 days old
· Has at least one hemangioma 1.5 cm in diameter
· Has not received previous treatment for hemangioma.

Infantile hemangiomas (IH) are red blemishes or bumps made up of small blood vessels. They affect around 3 to 10% of children born, and may appear on the head, face and neck in approximately 50% of cases. They are often not present at birth and usually become more obvious in the first weeks thereafter. Although many IHs shrink and disappear without medical intervention by the age of 10, some do not and may cause residual lesions and/ or complications including vision and airway obstruction. Current IH treatments include surgery, laser treatment, cryotherapy, corticosteroids and vincristine. The HEMANGIOL study looks to explore a new possibility by determining whether a treatment that is already licensed and used for various conditions in adults can reduce hemangioma growth in infants aged 35 – 150 days. The HEMANGIOL study will compare a placebo to propranolol in approximately 450 children with IH worldwide.

If you wish your child being seen to evaluate potential participation in this clinical trial, please contact:

- Sydney Children’s Hospital (Randwick - Sydney) - Dr Orli Wargon
Name of the person to contact : Susan Smith
Phone number: 9382 0512 or 0410 341 114
Email: susan.j.smith@sesiahs.health.nsw.gov.au

- Royal Children’s Hospital (Melbourne) - Dr Roderic Phillips
Name of the person to contact : Rod Phillips
Phone number: 03 93455522
Email: rod.phillips@rch.org.au

- Box Hill Hospital (Box Hill - Melbourne) - Dr John Su
Name of the person to contact : Althea Barr
Phone number: 9094 9544 or 0448 040 185
Email: althea.barr@monash.edu